{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:52:29Z","timestamp":1791579149803,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U24CA180803"],"award-info":[{"award-number":["U24CA180803"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CTEP"],"award-info":[{"award-number":["CTEP"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CIMAC"],"award-info":[{"award-number":["CIMAC"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.08.075","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:11:15Z","timestamp":1789225875000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1\u2013High Locally Advanced Non-small Cell Lung Cancer"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-0634","authenticated-orcid":false,"given":"Steven H.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane Marie Del","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Roudko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Doemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia","family":"Rizakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Mugunthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Beckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Gonzalez-Kozlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumil","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Bikkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagla","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahed N.","family":"Badiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin A.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Chakravarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Werner-Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Schallenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayte","family":"Suarez-Farinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.08.075_bib0001","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1183\/16000617.0053-2015","article-title":"Radio(chemo)therapy in locally advanced nonsmall cell lung cancer","volume":"25","author":"Glatzer","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0004","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5694\/mja2.12046","article-title":"Radiotherapy and immunotherapy: A synergistic effect in cancer care","volume":"210","author":"Turgeon","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0006","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-21-0145","article-title":"Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease: Current status and future focus","volume":"27","author":"Turchan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0007","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective personalized radioimmunotherapy for locally advanced non\u2013small-cell lung cancer trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0008","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jamaoncol.2023.3309","article-title":"Durvalumab plus concurrent radiotherapy for treatment of locally advanced non\u2013small cell lung cancer: The DOLPHIN phase 2 nonrandomized controlled trial","volume":"9","author":"Tachihara","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0009","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/1097-0142(19800601)45:11<2744::AID-CNCR2820451108>3.0.CO;2-U","article-title":"A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group","volume":"45","author":"Perez","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1748-717X-7-33","article-title":"Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer","volume":"7","author":"Amini","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0011","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.prro.2017.03.005","article-title":"Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer","volume":"7","author":"Fang","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0012","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with stage II\/III non\u2013small cell lung cancer and poor performance status: A randomized clinical trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1546875","article-title":"Potential immunogenic modulation of hypo-fractionated radiotherapy at optimal schedules and the subsequent vaccine-like effect of local irradiation - A systematic review","volume":"15","author":"Singh","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13014-019-1287-z","article-title":"Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC","volume":"14","author":"Zhao","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0015","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ijrobp.2026.02.238","article-title":"Pretreatment risk model for radiation-induced lymphopenia is associated with adjuvant durvalumab efficacy in patients with unresectable stage III NSCLC","volume":"125","author":"van Rossum","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0016","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3389\/fimmu.2019.01315","article-title":"Development of a comprehensive antibody staining database using a standardized analytics pipeline","volume":"10","author":"Amir","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0017","series-title":"OlinkAnalyze: Facilitate analysis of proteomic data from Olink","author":"Nevola","year":"2025"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0018","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/bioinformatics\/btaa687","article-title":"Dream: Powerful differential expression analysis for repeated measures designs","volume":"37","author":"Hoffman","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical Bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0021","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non\u2013small cell lung cancer: The phase III PACIFIC-2 study","volume":"43","author":"Bradley","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0022","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/onco.13725","article-title":"A review of immunotherapy for stage III and metastatic non-small cell lung cancer and the rationale for the ECOG-ACRIN EA5181 study","volume":"26","author":"Varlotto","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0024","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.4049\/jimmunol.160.10.4738","article-title":"A critical role for IL-18 in the proliferation and activation of NK1.1+CD3\u2212 cells","volume":"160","author":"Tomura","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1667\/RR15367.1","article-title":"Comprehensive analysis of the kinetics of radiation-induced lymphocyte loss in patients treated with external beam radiation therapy","volume":"193","author":"Ellsworth","year":"2020","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0026","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3389\/fimmu.2018.02900","article-title":"CD5, an undercover regulator of TCR signaling","volume":"9","author":"Voisinne","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0027","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1615\/CritRevImmunol.v20.i4.30","article-title":"CD5 signal transduction: Positive or negative modulation of antigen receptor signaling","volume":"20","author":"Lozano","year":"2000","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0028","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1189\/jlb.0205059","article-title":"Fas-mediated death and sensory adaptation limit the pathogenic potential of autoreactive T cells after strong antigenic stimulation","volume":"78","author":"Ryan","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ijrobp.2026.08.075_bib0029","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1003050","article-title":"CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation","volume":"186","author":"Garaud","year":"2011","journal-title":"J Immunol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626042860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626042860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:37:30Z","timestamp":1791578250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626042860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"alternative-id":["S0360301626042860"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.08.075","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death Ligand-1\u2013High Locally Advanced Non-small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.08.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}